KARL FJELLSTAD: Open Payments
NPI 1235912544 · PUYALLUP, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$729 in 32 payments from 16 companies in 2025. Trend: 2023 $156 · 2024 $800 · 2025 $729
Food & beverage: $729
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 5 | $125 |
| Corcept Therapeutics | 3 | $95 |
| Lilly USA, LLC | 3 | $83 |
| ABBVIE INC. | 3 | $66 |
| AstraZeneca Pharmaceuticals LP | 2 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $42 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $39 |
| Dexcom, Inc. | 2 | $34 |
| PFIZER INC. | 2 | $32 |
Products named: TRELEGY ELLIPTA, Korlym, JARDIANCE, AIRSUPRA, CAPLYTA, QULIPTA, VOQUEZNA, JOURNAVX.
Industry payments across WA — which companies pay providers there.
